{"id":"NCT00710554","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia","officialTitle":"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex® in the Treatment of Subjects With Peripheral Neuropathic Pain, Associated With Allodynia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2006-10","completion":"2006-10","firstPosted":"2008-07-04","resultsPosted":"2012-09-14","lastUpdate":"2023-05-03"},"enrollment":246,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Pain","Peripheral Neuropathy"],"interventions":[{"type":"DRUG","name":"Sativex","otherNames":["GW-1000-02"]},{"type":"DRUG","name":"Placebo","otherNames":["GW-4001-01"]}],"arms":[{"label":"Sativex","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.","primaryOutcome":{"measure":"Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks)","timeFrame":"Day 7 to Day 98","effectByArm":[{"arm":"Sativex","deltaMin":-1.36,"sd":2.02},{"arm":"Placebo","deltaMin":-0.84,"sd":1.86}],"pValues":[{"comp":"OG000 vs OG001","p":"0.139"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":23},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["24420962"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":128},"commonTop":["Dizziness","Nausea","Fatigue","Headache","Vomiting"]}}